Literature DB >> 11086027

Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes.

S M Clee1, J J Kastelein, M van Dam, M Marcil, K Roomp, K Y Zwarts, J A Collins, R Roelants, N Tamasawa, T Stulc, T Suda, R Ceska, B Boucher, C Rondeau, C DeSouich, A Brooks-Wilson, H O Molhuizen, J Frohlich, J Genest, M R Hayden.   

Abstract

We and others have recently identified mutations in the ABCA1 gene as the underlying cause of Tangier disease (TD) and of a dominantly inherited form of familial hypoalphalipoproteinemia (FHA) associated with reduced cholesterol efflux. We have now identified 13 ABCA1 mutations in 11 families (five TD, six FHA) and have examined the phenotypes of 77 individuals heterozygous for mutations in the ABCA1 gene. ABCA1 heterozygotes have decreased HDL cholesterol (HDL-C) and increased triglycerides. Age is an important modifier of the phenotype in heterozygotes, with a higher proportion of heterozygotes aged 30-70 years having HDL-C greater than the fifth percentile for age and sex compared with carriers less than 30 years of age. Levels of cholesterol efflux are highly correlated with HDL-C levels, accounting for 82% of its variation. Each 8% change in ABCA1-mediated efflux is predicted to be associated with a 0.1 mmol/l change in HDL-C. ABCA1 heterozygotes display a greater than threefold increase in the frequency of coronary artery disease (CAD), with earlier onset than unaffected family members. CAD is more frequent in those heterozygotes with lower cholesterol efflux values. These data provide direct evidence that impairment of cholesterol efflux and consequently reverse cholesterol transport is associated with reduced plasma HDL-C levels and increased risk of CAD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11086027      PMCID: PMC381437          DOI: 10.1172/JCI10727

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease.

Authors:  M Bodzioch; E Orsó; J Klucken; T Langmann; A Böttcher; W Diederich; W Drobnik; S Barlage; C Büchler; M Porsch-Ozcürümez; W E Kaminski; H W Hahmann; K Oette; G Rothe; C Aslanidis; K J Lackner; G Schmitz
Journal:  Nat Genet       Date:  1999-08       Impact factor: 38.330

2.  Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency.

Authors:  A Brooks-Wilson; M Marcil; S M Clee; L H Zhang; K Roomp; M van Dam; L Yu; C Brewer; J A Collins; H O Molhuizen; O Loubser; B F Ouelette; K Fichter; K J Ashbourne-Excoffon; C W Sensen; S Scherer; S Mott; M Denis; D Martindale; J Frohlich; K Morgan; B Koop; S Pimstone; J J Kastelein; J Genest; M R Hayden
Journal:  Nat Genet       Date:  1999-08       Impact factor: 38.330

Review 3.  High-density lipoprotein: multipotent effects on cells of the vasculature.

Authors:  G W Cockerill; S Reed
Journal:  Int Rev Cytol       Date:  1999

4.  Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men.

Authors:  U Goldbourt; S Yaari; J H Medalie
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-01       Impact factor: 8.311

5.  Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1.

Authors:  S Rust; M Rosier; H Funke; J Real; Z Amoura; J C Piette; J F Deleuze; H B Brewer; N Duverger; P Denèfle; G Assmann
Journal:  Nat Genet       Date:  1999-08       Impact factor: 38.330

6.  Prebeta-1 HDL in plasma of normolipidemic individuals: influences of plasma lipoproteins, age, and gender.

Authors:  P M O'Connor; B R Zysow; S A Schoenhaus; B Y Ishida; S T Kunitake; J M Naya-Vigne; P N Duchateau; R F Redberg; S J Spencer; S Mark; M Mazur; D C Heilbron; R B Jaffe; M J Malloy; J P Kane
Journal:  J Lipid Res       Date:  1998-03       Impact factor: 5.922

7.  Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency.

Authors:  M Marcil; L Yu; L Krimbou; B Boucher; J F Oram; J S Cohn; J Genest
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-01       Impact factor: 8.311

8.  Plasma and fibroblasts of Tangier disease patients are disturbed in transferring phospholipids onto apolipoprotein A-I.

Authors:  A von Eckardstein; A Chirazi; S Schuler-Lüttmann; M Walter; J J Kastelein; J Geisel; J T Real; R Miccoli; G Noseda; G Höbbel; G Assmann
Journal:  J Lipid Res       Date:  1998-05       Impact factor: 5.922

Review 9.  P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy.

Authors:  S Gupta
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

Review 10.  ABCR unites what ophthalmologists divide(s)

Authors:  M A van Driel; A Maugeri; B J Klevering; C B Hoyng; F P Cremers
Journal:  Ophthalmic Genet       Date:  1998-09       Impact factor: 1.803

View more
  75 in total

Review 1.  Tangier disease as a test of the reverse cholesterol transport hypothesis.

Authors:  A R Tall; N Wang
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 2.  Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism.

Authors:  R A Hegele
Journal:  Am J Hum Genet       Date:  2001-10-26       Impact factor: 11.025

3.  Is it time to modify the reverse cholesterol transport model?

Authors:  A R Tall; N Wang; P Mucksavage
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

4.  Therapeutic modulation of cellular cholesterol efflux.

Authors:  N Wang; A R Tall
Journal:  Curr Atheroscler Rep       Date:  2001-09       Impact factor: 5.113

Review 5.  Reverse cholesterol transport: high-density lipoprotein's magnificent mile.

Authors:  Peter P Toth
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 6.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?

Authors:  Menno Vergeer; Adriaan G Holleboom; John J P Kastelein; Jan Albert Kuivenhoven
Journal:  J Lipid Res       Date:  2010-04-06       Impact factor: 5.922

Review 8.  Hepatic ABCA1 and VLDL triglyceride production.

Authors:  Mingxia Liu; Soonkyu Chung; Gregory S Shelness; John S Parks
Journal:  Biochim Biophys Acta       Date:  2011-10-06

Review 9.  ATP binding cassette transporter A1--key roles in cellular lipid transport and atherosclerosis.

Authors:  Neelam Srivastava
Journal:  Mol Cell Biochem       Date:  2002-08       Impact factor: 3.396

10.  Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis.

Authors:  David P Kelsell; Elizabeth E Norgett; Harriet Unsworth; Muy-Teck Teh; Thomas Cullup; Charles A Mein; Patricia J Dopping-Hepenstal; Beverly A Dale; Gianluca Tadini; Philip Fleckman; Karen G Stephens; Virginia P Sybert; Susan B Mallory; Bernard V North; David R Witt; Eli Sprecher; Aileen E M Taylor; Andrew Ilchyshyn; Cameron T Kennedy; Helen Goodyear; Celia Moss; David Paige; John I Harper; Bryan D Young; Irene M Leigh; Robin A J Eady; Edel A O'Toole
Journal:  Am J Hum Genet       Date:  2005-03-08       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.